Compared with solvent-based paclitaxel, albumin-bound nab-paclitaxel exhibits 10-fold higher mean Cmax of free paclitaxel and preclinical models have shown higher drug concentration to tumors and enhanced cell transport.

Updated results from the ongoing global phase 2 study with crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC).

Rapidly evolving sequencing technologies characterizing the cancer genome have shown that not only do germline and somatic alterations in DNA mediate genesis and progression of cancer, but they also are clinically important as diagnostic markers and therapeutic targets.

LUX-Lung 3, the largest prospective trial in patients with EGFR-mutation–positive advanced adenocarcinoma of the lung and the first pivotal trial in Asian and non-Asian patients with EGFR mutations, found afatinib significantly prolonged progression-free survival (PFS).

Low-dose CT screening may benefit individuals at an increased risk for lung cancer; however, uncertainty exists about the potential harms of screening and the generalizability of the results.

High-dose radiation therapy does not improve overall survival (OS) versus a standard radiotherapy dose in patients with locally advanced non−small-cell lung cancer (NSCLC); however, intensity modulated radiotherapy (IMRT) may lead to a better OS rate in patients with stage III disease.

KRAS is the most common driver mutation observed in lung cancer. Discovered in the 1980s, KRAS mutations were initially stereotyped in the literature as occurring primarily in heavy smokers.

Patients and their families often have a limited understanding of their illness and an inaccurate view of their prognosis; and patients face difficult decisions about their cancer treatment and end-of-life care. Yet, with increasing use of personalized therapy, survival can only increase.

This case focuses on a 64-year-old Hispanic female with type 2 diabetes mellitus who is diagnosed with estrogen-receptor (ER) and progesterone-receptor (PR) positive breast cancer.

This case takes a detailed look at a 71-year-old white female who had been previously diagnosed with a stage-2 invasive hormone-receptor (HR) negative, HER2-positive ductal carcinoma along with 4 of 9 axillary lymph nodes involved with metastatic disease.

This case of a 46-year-old premenopausal African American woman outlines therapeutic considerations for adjuvant therapy of metastatic estrogen-receptor negative (ER-), progesterone-receptor negative (PR-), HER2-negative, or triple-negative breast cancer (TNBC).

The experimental antibody-drug conjugate trastuzumab emtansine (T-DM1) has shown significant improvement in progression-free survival (PFS) compared with capecitabine plus lapatinib among patients with HER2+ locally advanced or metastatic breast cancer (MBC).

Adjuvant therapy including 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by weekly paclitaxel was associated with a slight but significant improvement in disease-free survival.

Several analyses of the international randomized phase 3 Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) plus exemestane versus exemestane alone for the treatment of postmenopausal women.

Taxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer.

The first-in-class, oral, potent, and selective small-molecule competitive inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, was found to have a durable overall response rate and a median progression-free survival of 8.1 months in patients with ALK-positive non–small-cell lung cancer (NSCLC).

Pomalidomide in combination with low-dose dexamethasone has shown a 30% overall response rate in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both, including those with prior transplant.

The combination of carfilzomib, lenalidomide, and low-dose dexamethasone has been shown to be highly active in patients with newly diagnosed multiple myeloma and provides rapid and deep responses.

Patients with metastatic cancer who received early palliative care intervention had immediate improvement in satisfaction with care and later improvement in quality of life (QOL) and symptom control compared with standard care.

Continuous androgen deprivation may be a preferred treatment option for hormone-sensitive metastatic prostate cancer in men with minimal disease spread, according to results of a long-term international phase 3 trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.

Patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer had significantly improved radiographic progression-free survival (rPFS) and showed a strong trend for increased overall survival (OS) following treatment with abiraterone acetate plus prednisone compared with prednisone alone.